Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 26-29 September 2016
During its monthly meeting this week, the European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) focused on the broad spectrum of its responsibilities which cover all aspects of the risk management of the use of medicines. The Committee did not initiate or conclude a referral. More information on all ongoing safety reviews is included in the table below.
The PRAC's full range of work includes pre-authorisation activities, such as the assessment of risk-management plans for medicines under evaluation including any studies or risk minimisation activities planned for authorised use. Post-authorisation activities also include risk management planning as well as the evaluation of periodic safety update reports (PSURs) to assess the safety and benefit-risk balance of a medicine throughout its lifecycle. The PRAC also evaluates safety signals, a key public-health function that ensures that new or changing safety issues are rapidly detected, evaluated and, when appropriate, product-labelling changes or restrictions are introduced for the benefit of patients.
Information on all topics discussed by the PRAC is available below in the agenda for the meeting. A record of the discussions held this week will be provided in the minutes of this meeting, which will be published following the next PRAC meeting at the end of October.
|Agenda - PRAC draft agenda of meeting 26-29 September 2016|
|Article-31 referral: Gadolinium-containing contrast agents||Under evaluation||PRAC adopted a list of outstanding issues to be addressed by the marketing-authorisation holders.|
|Article-20 procedure: Direct-acting antivirals for treatment of hepatitis C (interferon-free)||Under evaluation||PRAC continued its assessment|
|Article-31 referral: Factor VIII||Under evaluation||PRAC continued its assessment|
|Article-31 referral: Paracetamol-modified release||Under evaluation||PRAC continued its assessment|
|Article-31 referral: Retinoid-containing medicinal products||Under evaluation||PRAC continued its assessment|
|Article-20 procedure: SGLT2 inhibitors (previously Canagliflozin)||Under evaluation||PRAC continued its assessment|